Systematically identifying and validating repurposed FDA-approved drugs for over 160 autoimmune diseases using AI, knowledge graphs, and high-throughput experimental screening.
Developing next-generation mRNA-LNP therapeutics that selectively modulate or deplete pathogenic immune cells to treat type 1 diabetes, lupus, multiple sclerosis, and other severe autoimmune conditions.
Mapping the full antigenic landscape of Sjögren's disease using T-Scan technology to identify the drivers of autoimmune T cell responses and enable targeted therapies.
Repurposing topical MC903, an FDA-approved vitamin D analog, to trigger skin-derived bile acid synthesis and generate systemic anti-inflammatory effects in lupus nephritis.
Developing 10E5-1, an anti-activin A antibody delivered via mRNA-LNP, to suppress pathogenic antibody production and treat rheumatoid arthritis through a novel mechanism.
Identifying the autoantigens and T cell clonotypes driving immune attack in aplastic anemia to enable more precise diagnostics and targeted therapies.
Identifying GSPT1 as an essential, targetable vulnerability of skin-resident memory T cells to enable durable remission in chronic inflammatory skin diseases without systemic immunosuppression.
Developing VCAM-1-targeted lipid nanoparticles delivering IL-10 mRNA to reduce neuroinflammation and improve outcomes after intracerebral hemorrhage.
